Facebook
Twitter
LinkedIn

Media Center

CLSI’s First International Showcase Highlights Companies from FAST and FAST International Programs
Facebook
Twitter
LinkedIn

Left to Right: John George, CSO of Oppilotech, Ajay Mistry, CEO of Oppilotech, Søren Würtz, CINO of Precure, Patric Stenberg, CEO of Gesynta, and Gunilla Ekström, Co-Founder of Gesynta

CLSI’s first International Showcase kicked off with presentations by twelve companies to an audience of 200+ attendees at UCSF’s Byer’s Auditorium in Mission Bay on Tuesday June 11.  In addition to five Bay Area companies from CLSI’s Spring 2019 FAST and CARB-X programs, the Showcase included presentations from seven non-U.S. based companies who had been through CLSI’s FAST International Program.

Valentin Lubbe of the Nordic Mentor Network of Entrepreneurship (NOME) helps open the CLSI International Showcase of Startup and Emerging Companies

The presenting companies were: Fauna Bio (USA), which is building a drug discovery pipeline using data from natural animal models; Gedea Biotech (Sweden), developing antibiotic free, safe treatment of vaginal infections; Gesynta Pharma (Sweden), which is developing combined anti-inflammatory and vasodilatory treatments for microvascular diseases; MediTuner (Sweden), providing digital solutions for improved care, diagnosis and self-management of asthma; Metis Biosciences (USA),  which is developing a new class of antimicrobials for the treatment of drug-resistant bacterial infections; N1 Life (USA), which is developing an efficient drug delivery platform across a variety of biological barriers; Oppilotech (UK), which is utilizing systems biology and machine learning to build computational model of cells; PreCure (Denmark), which is reducing the impact and frequency of work-related repetitive strain injuries; Serenity Bioworks (Canada), which is developing an immune-compatible gene therapy platform; Tezted (Finland), which is diagnosing tick borne diseases; Trellis Biosciences (USA), a broad spectrum novel antibody targeting multiple species of drug-resistant bacteria, and; Unnatural Products (USA), a macrocycle discovery platform combining computational design and parallel synthesis.

Begun six years ago, FAST continues to defy industry norms with its impressive track record: 60 company graduates – only two of which are no longer functioning – have raised $848M, including 24 Series A (and beyond) financings, formed 14 strategic partnerships and produced five exits since participating in FAST.

Building upon this record, in 2018 CLSI broadened the program to serve non-U.S.-based companies. FAST International targets clusters that seek to help their life science startups build successful business strategies and gain commercial footholds in U.S. markets.

Read about the International Showcase in BioSpace News: 12 Biotech Companies to Watch: CLSI’s FAST Companies

FALL 2019 FAST Applications Open

Applications for the Fall 2019 program are open through July 19. Apply now. For information on the FAST program, contact Julie Harness at jharness@califesciences.org. For information on the FAST International program, contact Steve Karp at skarp@califesciences.org.